---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-321663"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:59:15.697660+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veru reports FY2025 net loss $22.7M, cash $15.8M; enobosarm Phase 2b PLATEAU to start Q1'26

## Summary
- Net loss from continuing ops $15.7M ($1.07/sh) vs $35.3M ($2.61/sh) prior year; total net loss $22.7M ($1.55/sh).
- Post year-end public offering net proceeds ~$23.4M; cash as of Sep 30, 2025 was $15.8M vs $24.9M prior year.
- FDA confirmed enobosarm 3 mg acceptable; incremental weight loss of ≥5% placebo-corrected at 52 weeks acceptable primary endpoint for approval.
- Phase 2b QUALITY: enobosarm 3 mg preserved 100% lean mass, reduced physical function decline (≥10% stair climb power) from 44.8% to 17.6% with semaglutide.
- Phase 2b PLATEAU of enobosarm 3 mg + GLP-1 RA in 200 obesity patients starts Q1 2026; interim results Q1 2027.

## SEC filing metadata
- accession: 0001193125-25-321663
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/0001193125-25-321663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-321663
- JSON: https://secwatch.observer/filing/0001193125-25-321663.json
- Plain text: https://secwatch.observer/filing/0001193125-25-321663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.